AlphaValue Corporate Services
Cette analyse a été commandée et financée par l’entreprise concernée et constitue donc un avantage non-monétaire mineur tel que défini par MIFID2

Crossject

CR
Bloomberg   ALCJ FP
Super Génériques  /  France  Web Site   |   Investors Relation
Les choses commencent à bouger... espérons-le.
Objectif
Potentiel 315 %
Cours (€) 1,90
Capi (M€) 78,1
Perf. 1S: 0,11 %
Perf. 1M: 13,9 %
Perf. 3M: -6,70 %
Perf Ytd: -61,3 %
Perf. relative/stoxx600 10j: 13,8 %
Perf. relative/stoxx600 20j: 13,5 %
Target Change05/09/2018 09:47

On its way to reaching the market

Changement d’Objectif de cours€ 17,8 vs 16,1+10,5 %

Changement d’EPS2018 : € -0,94 vs -0,36ns
2019 : € -0,79 vs -0,06ns

We have fine-tuned our numbers in the back of the group’s latest comments as well as integrating the new NTE to be developed (Terbutaline) instead of Apomorphine which is now on stand-by. This said, short-term numbers have little meaning (other than the group’s cash-burn) since first sales should be booked in FY20.



Changement de NAV€ 19,0 vs 18,2+4,78 %

We have adjusted our numbers to take into account Terbutaline, the new therapeutic entity the group expects to develop alongside the six previous ones (already in our numbers). Some minor short-term changes have also impacted current net debt.



Changement de DCF€ 24,9 vs 21,5+16,2 %

Our DCF valuation goes up quite significantly after we integrated Terbutaline and fine-tuned our numbers (volumes and prices) for the other NTEs the group plans to market.



Mises à Jour

24 déc. 18 EPS change
Ajustement du nombre d'actions

21 déc. 18 Dernière News
Succès de l'augmentation de capital

28 nov. 18 Question de financement
Augmentation de capital de 3,9m€

23 oct. 18 Autres News / Commentaires
Conversion d'obligations

05 sept. 18 Target Change
On its way to reaching the market

13 juil. 18 Question de financement
Une obligation convertible et des BSA potenten...

.